GlassScriptPhysician profile
Matthew A Sauder
NPI 1124245972
$775.60
in general payments reported to CMS, 2019-2025
23 companies · $17.32 in 2025
The $17.32 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $79.80 · 2021: $61.89 · 2022: $203 · 2023: $145 · 2025: $17.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $188.79 | 2020-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Mannkind Corporation | $101.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $51.40 | 2019-2023 | |
| Insulet Corporation | $46.78 | 2019 | |
| Valeritas, INC. | $43.26 | 2019 | |
| Medtronic, INC. | $32.75 | 2022-2025 | Minimed 780g |
| Becton, Dickinson and Company | $27.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.26 | 2019 | |
| Antares Pharma, INC. | $23.78 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.91 | 2019 | |
| Abbott Laboratories | $22.68 | 2019 | |
| Recordati_rare_diseases_inc. | $19.21 | 2023 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $18.80 | 2019 | |
| Corcept Therapeutics | $18.61 | 2019 | |
| Horizon Therapeutics Plc | $18.16 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.85 | 2019 | |
| Averitas Pharma INC. | $16.03 | 2023 | Qutenza |
| Senseonics, Incorporated | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.84 | 2019 | |
| Kci USA, INC. | $14.08 | 2023 | Prevena Restor Arthroform, Prevena |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2023 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Novo Nordisk INC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sauder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.